Portal de Periódicos da CAPES

Sublingual midazolam premedication in children: a dose response study

1998; Wiley; Volume: 8; Issue: 6 Linguagem: Inglês

10.1046/j.1460-9592.1998.00286.x

1460-9592

Samia N. Khalil, Lisa Philbrook, Mary Rabb, Kari Wagner, Chris Jennings, Alice Z. Chuang, Noreen A. Lemak,

Healthcare Decision-Making and Restraints

The purpose of this study was to evaluate various doses of sublingual midazolam premedication in children. In our prospective, double‐blind, placebo‐controlled trial, children ( n =102, age range 12 to 129 months) scheduled for day surgery were randomized to receive either midazolam in one of three doses (0.25, 0.5, or 0.75 mg·kg −1 ) or placebo. Injectable midazolam was mixed with a thick grape syrup and placed under the tongue; the patient was asked to hold it as long as possible before swallowing. Children readily accepted the mixture. Analysing all patients randomized, none of the children receiving placebo vs 28% receiving 0.25 mg·kg −1 ( P =0.02), 52% receiving 0.5 mg·kg −1 ( P <0.001), and 64% receiving 0.75 mg·kg −1 ( P <0.001) of midazolam showed satisfactory sedation (drowsy) at 15 min after administration. Children receiving the two higher doses of midazolam (0.5 and 0.75 mg·kg −1 ) accepted mask induction willingly, while the group receiving 0.25 mg·kg −1 resembled the placebo group ( P <0.05).